A phase II study of Bevacizumab plus Paclitaxel followed by Eribulin maintenance therapy in patients with HER2-negative metastatic breast cancer.

Trial Profile

A phase II study of Bevacizumab plus Paclitaxel followed by Eribulin maintenance therapy in patients with HER2-negative metastatic breast cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Eribulin (Primary) ; Bevacizumab; Paclitaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2017 Planned number of patients changed from 43 to 53.
    • 23 Mar 2016 Planned End Date changed from 31 Dec 2016 to 31 Dec 2020.
    • 23 Mar 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top